Financial Performance - The company's revenue for Q1 2025 was ¥188,034,307.73, a decrease of 22.23% compared to ¥241,778,598.22 in the same period last year[5] - Net profit attributable to shareholders was ¥19,044,819.05, down 26.64% from ¥25,961,526.88 year-on-year[5] - Basic earnings per share decreased to ¥0.0323, down 26.09% from ¥0.0437 in the same period last year[5] - Net profit for the period was ¥19,044,700.74, down from ¥28,081,767.64, a decrease of approximately 32.3% year-over-year[25] - Total operating revenue decreased to ¥188,034,307.73 from ¥241,778,598.22, a decline of approximately 22.2% year-over-year[24] - Total operating costs decreased to ¥165,982,769.88 from ¥209,838,876.06, representing a reduction of about 20.9% year-over-year[24] Cash Flow - The net cash flow from operating activities was -¥37,532,983.25, a significant decline of 298.94% compared to -¥9,408,089.36 in the previous year[5] - The net cash flow from investing activities was -¥7,885,034.85, a decline of 186.17% compared to ¥9,150,743.28 in the previous year[11] - The net cash flow from financing activities was -¥4,808,713.19, a decrease of 284.78% compared to ¥2,602,340.67 in the previous year, primarily due to share repurchase activities[11] - Cash inflow from operating activities totaled $132.76 million, a decrease of 2.3% from the previous period's $136.28 million[28] - Cash outflow from operating activities increased to $170.29 million, up 16.8% from $145.68 million in the prior period[29] - Net cash flow from operating activities was -$37.53 million, worsening from -$9.41 million year-over-year[29] - Cash inflow from investment activities was $941.57 million, significantly higher than $33.22 million in the previous period[29] - Cash outflow from investment activities rose to $949.46 million, compared to $24.07 million last year[29] - Net cash flow from investment activities was -$7.89 million, a decline from $9.15 million in the prior period[29] - Cash inflow from financing activities increased to $40 million, up from $3 million in the previous period[29] - Cash outflow from financing activities totaled $44.81 million, compared to $0.40 million last year[29] - Net cash flow from financing activities was -$4.81 million, a decrease from $2.60 million in the prior period[29] - The ending cash and cash equivalents balance was $447.83 million, down from $715.79 million in the previous period[29] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,592,174,782.52, a decrease of 1.25% from ¥2,624,919,556.21 at the end of the previous year[5] - Total liabilities decreased to ¥873,847,735.56 from ¥885,496,289.52, a decline of about 1.5%[22] - Non-current liabilities increased to ¥604,607,479.99 from ¥561,724,206.32, an increase of approximately 7.6%[22] - The company reported a decrease in cash and cash equivalents from 532,101,881.48 yuan to 477,954,713.78 yuan[20] - Accounts receivable increased from 206,201,924.73 yuan to 212,619,685.82 yuan, indicating a rise in credit sales[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 22,262[13] - The largest shareholder, Qingdao Guoen Technology Co., Ltd., holds 21.18% of shares, totaling 125,711,022 shares, with 88,000,000 shares pledged[13] - Hainan Bainashengyuan Technology Co., Ltd. holds 5.62% of shares, totaling 33,335,422 shares, with 23,320,000 shares pledged[13] - The top 10 shareholders collectively hold significant stakes, with the first three shareholders accounting for over 29% of total shares[13] - The total number of restricted shares at the end of the period is 3,846,150 shares, with 116,287 shares released from restriction[16] Research and Development - Research and development expenses increased by 41.41% to ¥5,722,250.85, compared to ¥4,046,567.55 in the previous year[10] - Research and development expenses increased to ¥5,722,250.85 from ¥4,046,567.55, an increase of about 41.4% year-over-year[25] Other Information - The company reported a significant increase in long-term borrowings, rising by 111.02% to ¥76,073,833.34 from ¥36,050,000.00[10] - The company recorded a profit from asset disposal of ¥10,571.31, a 103.78% increase compared to a loss of ¥279,378.71 in the previous year[10] - The company has disclosed a share repurchase plan, with further details available on the official website[18] - The report indicates that the company is actively managing its shareholder structure and financial assets to enhance shareholder value[18] - Cash flow from operating activities details not provided in the extracted data[27] - Future outlook and strategic initiatives were not detailed in the provided content[27]

Group 1 - The core viewpoint of the articles highlights the importance of share buybacks as a value management tool in the capital market, especially following the release of new policies that support stock repurchase initiatives [1] - The company Dongbao Biological Technology Co., Ltd. has actively implemented its share buyback plan, with a total repurchase amount exceeding 40 million RMB as of March 31, 2025 [1] - The share buyback plan aims to optimize incentive systems, enhance innovation culture, and maintain company value and shareholder rights, thereby boosting investor confidence [1] Group 2 - Dongbao Biological is committed to advancing its "Collagen+" strategy to build a premium collagen brand, focusing on extending the industrial chain and enhancing the value chain [2] - The company plans to deepen its development in the health industry through high-quality growth and innovation, while also improving its core competitiveness [2] - The strategic focus includes comprehensive planning across brand, market, innovation, service, investment, and management to solidify its leading position in the collagen industry [2]

Core Viewpoint - Dongbao Biological is actively promoting its share repurchase plan to enhance employee incentive mechanisms and support its strategic goals in the collagen industry [1][2] Group 1: Share Repurchase Plan - The company approved a share repurchase plan on January 3, intending to use its own and/or raised funds to buy back its A-shares through centralized bidding or other legal methods [1] - The repurchase amount is set between RMB 50 million and RMB 100 million, with a maximum repurchase price of RMB 8.00 per share [1] - As of March 31, the company has repurchased 7.348 million shares, accounting for 1.2379% of the total share capital, with a total transaction amount of RMB 40.1431 million [1] Group 2: Strategic Focus and Goals - Dongbao Biological focuses on the collagen industry, aiming to innovate and deepen the application of collagen across medical, health, food, and beauty sectors [1] - The company plans to create a vertically integrated product strategy, enhancing brand and channel collaboration to diversify and increase revenue [2] - The goal is to become a leading brand in the domestic collagen market and a comprehensive enterprise group in the health industry, emphasizing scale, platform, and brand benefits [2]

证券代码：300239 证券简称：东宝生物 公告编号：2025-021 债券代码：123214 债券简称：东宝转债 包头东宝生物技术股份有限公司 二、其他情况说明 (一)公司回购股份的时间、回购股份数量及集中竞价交易的委托时段、交易 价格等符合《深圳证券交易所上市公司自律监管指引第9号——回购股份》及公 司回购股份方案的相关规定。 1、公司未在下列期间内回购公司股份： (1)自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项发 生之日或者在决策过程中，至依法披露之日内； 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司(以下简称"东宝生物"或"公司")于2025 年1月3日召开第九届董事会第八次会议、第九届监事会第七次会议，审议通过了 《关于回购公司股份方案的议案》，使用公司自有资金和/或自筹资金以集中竞 价交易方式或法律法规允许的方式回购公司已发行的人民币普通股(A股)股票， 回购的公司股份用于实施员工持股计划或股权激励。本次回购股份不低于人民币 5,000万元(含)，且不超过人民币10,00 ...

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-020 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、"东宝转债"(债券代码：123214)的转股期限为2024年2月5日至2029年7月30日； 最新有效的转股价格为6.65元/股。 2、2025年第一季度，共有58张"东宝转债"(票面金额共计5,800元人民币)完成转股， 合计转成871股"东宝生物"(股票代码：300239)股票。 3、截止 2025 年第一季度末，公司剩余可转债为 4,549,670 张，剩余票面总金额为 454,967,000 元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司自律监 管指引第15号——可转换公司债券》的有关规定，包头东宝生物技术股份有限公司(以 下简称"公司"或"东宝生物")现将2025年第一季度可转换公司债券转股及公司总股本变 化情况公告如下： 一、可转换公司债券发行及上市情况 (一)可转债发 ...

招商证券股份有限公司 关于包头东宝生物技术股份有限公司 2024 年度定期现场检查报告 | 保荐人名称：招商证券股份有限公司 被保荐公司简称：东宝生物 | | | --- | --- | | 保荐代表人姓名：留梦佳 联系电话：021-58835130 | | | 保荐代表人姓名：周冰昱 联系电话：021-58835130 | | | 现场检查人员姓名：留梦佳、周冰昱 | | | 现场检查对应期间：2024 年度 | | | 现场检查时间：2025 年 3 月 3 日至 2025 年 3 月 7 日 | | | 一、现场检查事项 现场检查意见 | | | （一）公司治理 是 否 | 不适用 | | 现场检查手段：查阅历次三会会议资料；查阅公司章程、公司现行有效的各项规章制度；核 | | | 查是否存在同业竞争和显失公平的关联交易等违规情况；取得公司组织结构图、股东名册等 | | | 资料；实地查看公司经营场所；对公司相关人员进行访谈。 | | | 1.公司章程和公司治理制度是否完备、合规 √ | | | 2.公司章程和三会规则是否得到有效执行 √ | | | 3.三会会议记录是否完整，时间、地点、出席人员及会议 ...

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-018 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 包头东宝生物技术股份有限公司 第九届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 3、会议出席人员：本次会议应出席董事 7 名，实际出席董事 7 名(其中，现 场出席 2 名，通讯出席 5 名)。董事长王爱国先生、董事兼副总经理刘燕女士、 独立董事任斌先生、独立董事额尔敦陶克涛先生、独立董事王京先生以通讯方式 出席了本次会议，董事兼总经理刘芳先生、董事兼副总经理王富荣先生出席了现 场会议。 4、会议列席人员：公司监事会主席孙红喜女士、监事王珺女士、副总经理 王刚先生以通讯方式列席了本次会议，监事杜学文先生、财务总监郝海青先生、 副总经理兼董事会秘书单华夷女士、副总经理杜建光先生列席了现场会议。 一、董事会会议召开情况 1、包头东宝生物技术股份有限公司(以下简称"公司")第九届董事会第九 次会议通知于 2025 年 3 月 14 日以电话、口头或直接送 ...

| 债券代码：123214 | 债券简称：东宝转债 | | | --- | --- | --- | | 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-019 | 包头东宝生物技术股份有限公司 关于不向下修正"东宝转债"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 自2025年2月24日至2025年3月14日，包头东宝生物技术股份有限公司(以下简 称"公司")股票已有十五个交易日的收盘价低于当期转股价格6.65元/股的90%，已 触发"东宝转债"转股价格向下修正条件。公司于2025年3月14日召开第九届董事会 第九次会议，审议通过了《关于不向下修正"东宝转债"转股价格的议案》，公司 董事会决定本次不向下修正"东宝转债"转股价格，同时自本次董事会审议通过次 一交易日起至2025年9月16日，如再次触发"东宝转债"转股价格向下修正条件，亦 不提出向下修正方案。在此期间之后(从2025年9月17日重新起算)，若再次触发"东 宝转债"转股价格向下修正条件，届时公司董事会将再次召开会议决定是否行使 "东宝转债"的转股 ...

| | | 债券代码：123214 债券简称：东宝转债 包头东宝生物技术股份有限公司 关于东宝转债预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300239，证券简称：东宝生物 2、债券代码：123214，债券简称：东宝转债 3、转股价格：6.65 元/股 4、转股期限：2024 年 2 月 5 日至 2029 年 7 月 30 日 5、根据公司《包头东宝生物技术股份有限公司向不特定对象发行可转换公司 债券募集说明书》(以下简称"《募集说明书》")规定：在本次发行的可转换公 司债券存续期间，当公司 A 股股票在任意连续三十个交易日中至少有十五个交易 日的收盘价低于当期转股价格的 90%时，公司董事会有权提出转股价格向下修正方 案并提交公司股东大会审议表决。 一、可转换公司债券基本情况 1、可转换公司债券发行情况 经中国证券监督管理委员会出具的《关于同意包头东宝生物技术股份有限公司 向不特定对象发行可转换公司债券注册的批复》(证监许可﹝2023﹞1517 号)同意注 册，公司向不特定对象发行 ...

证券代码：300239 证券简称：东宝生物 公告编号：2025-016 债券代码：123214 债券简称：东宝转债 包头东宝生物技术股份有限公司 1、公司未在下列期间内回购公司股份： 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司(以下简称"东宝生物"或"公司")于2025 年1月3日召开第九届董事会第八次会议、第九届监事会第七次会议，审议通过了 《关于回购公司股份方案的议案》，使用公司自有资金和/或自筹资金以集中竞 价交易方式或法律法规允许的方式回购公司已发行的人民币普通股(A股)股票， 回购的公司股份用于实施员工持股计划或股权激励。本次回购股份不低于人民币 5,000万元(含)，且不超过人民币10,000万元(含)，具体回购资金总额以回购期限 届满时或者回购股份实施完毕时实际回购股份使用的成交资金总额为准。本次回 购价格不超过人民币8.00元/股(含)，本次回购股份的实施期限自公司董事会审议 通过回购股份方案之日起12个月内。具体内容详见公司在巨潮资讯网 (www.cninfo.com.cn)上披露 ...